Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancerPaolo Tarantino, Sarah Sammons, Ian E. Krop et al.|ESMO Open|2025Cited by 19
Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast CancerSida Huang, Michaela A. Dinan, Sarah J. Westvold et al.|JAMA Network Open|2025Cited by 16
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Paolo Tarantino, Sarah Sammons, Do Kyeong Lee et al.|Journal of Clinical Oncology|2024Cited by 13
Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival AnalysisD. Bui, Roy H. Decker, William J. Magnuson et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 0